Research Reports

Crystal Research Report by Jeffrey Kraws

"In April 2011, Adamis' biotechnology unit completed the acquisition of a novel technology forming the basis for a prostate cancer vaccine called TeloB-VAX. TeloB-VAX is scheduled to enter Phase II studies, for which an Investigational New Drug (IND) application will likely be filed in the fourth quarter 2011. Going forward, the vaccine platform may be able to treat other tumor types, such as lung, breast, and colon cancers, as well as viral diseases, including chronic hepatitis, human papilloma virus (HPV), and influenza."

You can download the full report here:Crystal Research Report on Adamis Pharmaceuticals